Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2013

View Archived Issues

Activity of AXL/c-Met inhibitor CEP-40783 described in vitro and in vivo

Bayer Schering Pharma synthesizes new Mnk1 inhibitors for cancer

Cubist completes acquisition of Optimer Pharmaceuticals

Amgen reports active third quarter 2013

Merck Serono and Selvita enter oncology collaboration targeting metabolic pathways

Merck & Co. plans BLA submission for multivalent HPV vaccine

Intranasal formulation of teriparatide may improve compliance

Shire announces reorganization progress of third quarter 2013

Potent, small-molecule, pyridopyrimidinone inhibitor of schwannoma tumorigenesis described

Development and characterization of a first-in-class bacterial inhibitor

Clinical trials show efficacy of netupitant/palonosetron combination

FDA committee supports approval of simeprevir as part of combination therapy for hepatitis C

FDA approves GE Healthcare's brain imaging drug for Alzheimer's disease and dementia

Five Prime provides update on two antibody candidates entering phase I trials

Pfizer discloses new DGAT2 inhibitors

Novel stem cell microparticles claimed by ReNeuron

New chimeric/humanized antibodies bind to human tau protein

Tissue Therapies files application to conduct pivotal VitroGro ECM trial

NovelMed Therapeutics divulges new monoclonal antibodies

Novel nucleic acid vectors presented by Columbia University

ViiV Healthcare files single-tablet regimen MAA for people living with HIV

Imugene executes sale and purchase agreement to acquire Biolife Science

Zohydro ER approved by the FDA for pain

EMA committee recommends approval of Lundbeck's Brintellix

CHMP issues opinion on compassionate use of Gilead's sofosbuvir for chronic HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...